Jhundoo Henusha D, Siefen Tobias, Liang Alfred, Schmidt Christoph, Lokhnauth John, Moulari Brice, Béduneau Arnaud, Pellequer Yann, Larsen Crilles Casper, Lamprecht Alf
Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.
Tris Pharma, Monmouth Junction, NJ 08852, USA.
Int J Pharm X. 2021 Apr 24;3:100080. doi: 10.1016/j.ijpx.2021.100080. eCollection 2021 Dec.
Findings from recent studies revealed a significant anti-inflammatory effect of polysaccharide-based excipients when formulated with classical drugs in experimental inflammatory bowel disease models. In this study, acacia and guar gum were investigated beyond their typical functionality for a possible additive anti-inflammatory effect when administered with 5-amino salicylic acid (5ASA) in murine experimental colitis. Anti-inflammatory effects of acacia and guar gum-based aqueous suspensions of 5ASA were evaluated in a murine experimental colitis. Acacia or guar gum (30 or 300 mg/kg) were administered rectal administration alone or in combination with 5ASA (30 mg/kg). Disease activity, myeloperoxidase activity (MPO) and intratissue concentrations of various cytokines were assessed. Both acacia and guar gum separately showed significant effects in reducing the inflammatory markers in murine colitis model . When combined with the anti-inflammatory drug 5ASA, acacia showed a stronger therapeutic effect than guar gum, especially at the higher dose of acacia (300 mg/kg) which significantly reduced the inflammation compared to 5ASA alone (MPO, 5ASA: 5743 ± 1334, 5ASA + 30 mg/kg acacia: 3762 ± 2342; 5ASA + 30 mg/kg guar gum: 7373 ± 2115, 5ASA + 300 mg/kg acacia: 3131 ± 1012, 5ASA + 300 mg/kg guar gum: 6358 ± 2379; all U/g tissue). Acacia and guar gum separately showed significant anti-inflammatory effects in murine colitis, and furthermore, high dose acacia led to an additional therapeutic benefit when co-administered with 5ASA. These results indicate that further investigations are surely warranted in the search of better colitis therapy.
近期研究结果显示，在实验性炎症性肠病模型中，多糖类辅料与传统药物配制成制剂时具有显著的抗炎作用。在本研究中，对阿拉伯胶和瓜尔胶进行了研究，考察了它们在与5-氨基水杨酸（5ASA）联合给药于小鼠实验性结肠炎时，除其典型功能外是否还具有额外的抗炎作用。评估了基于阿拉伯胶和瓜尔胶的5ASA水悬浮液在小鼠实验性结肠炎中的抗炎作用。单独或与5ASA（30mg/kg）联合经直肠给予阿拉伯胶或瓜尔胶（30或300mg/kg）。评估疾病活动度、髓过氧化物酶活性（MPO）以及各种细胞因子的组织内浓度。阿拉伯胶和瓜尔胶单独使用时均在降低小鼠结肠炎模型中的炎症标志物方面显示出显著效果。当与抗炎药物5ASA联合使用时，阿拉伯胶显示出比瓜尔胶更强的治疗效果，尤其是在较高剂量的阿拉伯胶（300mg/kg）时，与单独使用5ASA相比，其显著减轻了炎症（MPO，5ASA：5743±1334，5ASA+30mg/kg阿拉伯胶：3762±2342；5ASA+30mg/kg瓜尔胶：7373±2115，5ASA+300mg/kg阿拉伯胶：3131±1012，5ASA+300mg/kg瓜尔胶：6358±2379；均为U/g组织）。阿拉伯胶和瓜尔胶在小鼠结肠炎中单独显示出显著的抗炎作用，此外，高剂量阿拉伯胶与5ASA联合给药时可带来额外的治疗益处。这些结果表明，为寻求更好的结肠炎治疗方法，进一步的研究确有必要。
